首页 > 市场调查报告书 > 製药

神经疾病

多发性硬化症市场规模、份额和成长分析（按药物类别、诊断、给药途径、通路、最终用户和地区划分）－产业预测（2026-2033年）

市场调查报告书

商品编码

1898528

多发性硬化症市场规模、份额和成长分析（按药物类别、诊断、给药途径、通路、最终用户和地区划分）－产业预测（2026-2033年）

Multiple Sclerosis Market Size, Share, and Growth Analysis, By Drug Class (Immunomodulators, Immunosuppressants), By Diagnosis, By Route of Administration, By Distribution Channel, By End-Users, By Region - Industry Forecast 2026-2033

出版日期: 2025年12月23日 | 出版商:

SkyQuest | 英文 214 Pages | 商品交期: 3-5个工作天内

价格

简介目录

预计到 2024 年，全球多发性硬化症 (MS) 市场规模将达到 266.4 亿美元，到 2025 年将达到 272.5 亿美元，到 2033 年将达到 326.9 亿美元，预测期（2026-2033 年）的复合年增长率为 2.3%。

全球多发性硬化症 (MS) 的发展趋势表明，由于其免疫介导的疾病特征会严重损害中枢神经系统，因此对创新治疗方法的需求日益增长。脱髓鞘和轴突丧失等关键病理状况凸显了有效治疗方法的迫切性。去髓鞘化抗体，包括人源化单株抗体，处于治疗研发的前沿，目前正在进行大量临床试验以发现新药。 MS 盛行率的上升凸显了诊断和治疗的重要性，促使政府加强对治疗的支持。为了推动市场发展，主要企业正致力于研发，同时，製药公司与学术机构之间的合作也进一步促进了 MS 治疗的进步，从而催生了一个快速发展的製药行业，该行业专注于解决影响患者的各种症状。

全球多发性硬化症市场驱动因素

多发性硬化症盛行率的不断上升是市场扩张的主要驱动力。这种神经系统疾病有多种类型，包括復发缓解型多发性硬化症 (RRMS)、首发渐进型(PPMS)、次发渐进型(SPMS) 和渐进復发型(PRMS)，每种类型都有较高的盛行率，并对市场动态产生影响。随着这些不同类型多发性硬化症发病率的持续上升，对有效治疗方法和先进治疗方法的需求也在不断增长，从而推动了该领域的创新和投资。人们对该疾病的认识不断提高，并寻求更好的治疗方案，这些因素共同促进了全球多发性硬化症市场的整体成长。

限制全球多发性硬化症市场的因素

全球多发性硬化症市场成长可能受到多种因素的限制。高昂的治疗费用可能限制患者获得治疗的机会，进而抑制市场扩张。此外，在开发中国家，医疗基础设施和合格医护人员的匮乏进一步阻碍了治疗的普及。近期发生的健康危机也导致就医率下降，这可能会影响患者的治疗顺从性和治疗的连续性。此外，大众对多发性硬化症认知的普遍不足也为患者教育和诊断带来了挑战，最终阻碍因素了市场的整体成长潜力。

全球多发性硬化症市场趋势

全球多发性硬化症市场正呈现出显着的发展趋势，主要得益于研发领域的庞大投资。製药公司致力于开发创新治疗方法以应对这种复杂的疾病，从而推动了竞争激烈的市场格局，其中活跃的临床试验和研究合作尤为突出。包括选择性受体拮抗剂在内的新型治疗方法的出现，预示着充满活力的研发管线有望改善患者的治疗效果。随着各相关人员积极拓展产品组合，这种活性化的研发活动不仅有望带来突破性治疗方法，还将推动市场更广泛地扩张，最终重塑多发性硬化症治疗的未来。

北美洲
- 美国
- 加拿大
欧洲
- 德国
- 西班牙
- 法国
- 英国
- 义大利
- 其他欧洲地区
亚太地区
- 中国
- 印度
- 日本
- 韩国
- 亚太其他地区
拉丁美洲
- 巴西
- 其他拉丁美洲地区
中东和非洲
- 海湾合作委员会国家
- 南非
- 其他中东和非洲地区

竞争资讯

前五大公司对比
主要企业的市场定位（2025 年）
主要市场参与者所采取的策略
近期市场趋势
公司市占率分析（2025 年）
主要企业公司简介
- 公司详情
- 产品系列分析
- 依业务板块进行公司股票分析
- 2023-2025年营收年比比较

主要企业简介

Biogen Inc.（United States）
Teva Pharmaceutical Industries Ltd.（Israel）
Novartis AG（Switzerland）
Roche Holding AG（Switzerland）
Key Developments
Merck KGaA（Germany）
Bayer AG（Germany）
Johnson & Johnson（United States）
AbbVie Inc.（United States）
TG Therapeutics, Inc.（United States）
Acorda Therapeutics, Inc.（United States）
Alkermes plc（Ireland）
H. Lundbeck A/S（Denmark）
Eli Lilly and Company（United States）
GlaxoSmithKline plc（United Kingdom）
Pfizer Inc.（United States）
Celgene Corporation（United States）
Mallinckrodt Pharmaceuticals（United Kingdom）
UCB SA（Belgium）
Orion Corporation（Finland）

结论与建议

简介目录

Product Code: SQMIG35G2271

Global Multiple Sclerosis Market size was valued at USD 26.64 Billion in 2024 and is poised to grow from USD 27.25 Billion in 2025 to USD 32.69 Billion by 2033, growing at a CAGR of 2.3% during the forecast period (2026-2033).

The global multiple sclerosis (MS) landscape showcases a growing demand for innovative treatments, driven by the condition's immune-mediated nature that disrupts the central nervous system. Key characteristics, such as demyelination and neuroaxonal loss, highlight the urgent need for effective therapies. Monoclonal antibodies, including humanized variants, are at the forefront of treatment development, with numerous clinical trials aimed at discovering new drugs. The rising prevalence of MS emphasizes the significance of diagnosis and therapy, prompting government support for treatment initiatives. To fuel this market, major players are increasingly focusing on research and development, while collaborative efforts between pharmaceutical companies and academic institutions are further stimulating advancements in MS therapeutics, leading to a burgeoning drug industry focused on addressing diverse symptoms impacting patients.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Multiple Sclerosis market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Multiple Sclerosis Market Segments Analysis

Global Multiple Sclerosis Market is segmented by Drug Class, Diagnosis, Route of Administration, Distribution Channel, End-Users and region. Based on Drug Class, the market is segmented into Immunomodulators, Immunosuppressants, Interferons and Others. Based on Diagnosis, the market is segmented into Magnetic Resonance Imaging (MRI), Simple Electrical Stimulation Tests, Lumbar Puncture and Others. Based on Route of Administration, the market is segmented into Oral, Parenteral and Others. Based on Distribution Channel, the market is segmented into Hospital Pharmacy, Retail Pharmacy, Online Pharmacy and Others. Based on End-Users, the market is segmented into Hospitals, Specialty Clinics, Homecare and Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Multiple Sclerosis Market

The growing prevalence of multiple sclerosis significantly fuels the expansion of the market. This neurological condition presents in various forms, including relapsing-remitting multiple sclerosis (RRMS), primary-progressive MS (PPMS), secondary-progressive MS (SPMS), and progressive-relapsing MS (PRMS), each demonstrating a notable incidence that influences market dynamics. As the rates of these different types continue to rise, the demand for effective treatments and advanced therapies increases, driving innovation and investment within the sector. This heightened awareness and the search for better management options contribute to the overall growth trajectory of the global multiple sclerosis market.

Restraints in the Global Multiple Sclerosis Market

The growth of the global multiple sclerosis market may be hindered by several factors. The high costs associated with treating the disease can restrict accessibility and limit market expansion. Additionally, developing countries may struggle with insufficient healthcare infrastructure and a lack of qualified professionals, further complicating treatment availability. The repercussions of recent health crises have also led to a decline in clinical visits, which can impact patient engagement and care continuity. Moreover, widespread gaps in awareness surrounding multiple sclerosis contribute to challenges in patient education and diagnosis, ultimately acting as constraints on the overall growth potential of the market.

Market Trends of the Global Multiple Sclerosis Market

The Global Multiple Sclerosis market is witnessing a notable trend driven by substantial investments in research and development. Pharmaceutical companies are increasingly focused on advancing innovative treatment modalities to address this complex disease, fostering a competitive landscape characterized by robust clinical trials and collaborations with research institutions. The emergence of novel therapies, including selective receptor antagonists, is indicative of a thriving pipeline that promises to enhance patient outcomes. As various stakeholders actively engage in expanding their portfolios, this heightened R&D activity is poised to not only introduce groundbreaking therapies but also catalyze broader market expansion, ultimately reshaping the future of multiple sclerosis management.

Introduction

Objectives of the Study
Scope of the Report
Definitions

Research Methodology

Information Procurement
Secondary & Primary Data Methods
Market Size Estimation
Market Assumptions & Limitations

Executive Summary

Global Market Outlook
Supply & Demand Trend Analysis
Segmental Opportunity Analysis

Market Dynamics & Outlook

Market Overview
Market Size
Market Dynamics
- Drivers & Opportunities
- Restraints & Challenges
Porters Analysis
- Competitive rivalry
- Threat of substitute
- Bargaining power of buyers
- Threat of new entrants
- Bargaining power of suppliers

Key Market Insights

Key Success Factors
Degree of Competition
Top Investment Pockets
Market Ecosystem
Market Attractiveness Index, 2025
PESTEL Analysis
Macro-Economic Indicators
Value Chain Analysis
Pricing Analysis

Global Multiple Sclerosis Market Size by Drug Class & CAGR (2026-2033)

Market Overview
Immunomodulators
Immunosuppressants
Interferons
Others

Global Multiple Sclerosis Market Size by Diagnosis & CAGR (2026-2033)

Market Overview
Magnetic Resonance Imaging (MRI)
Simple Electrical Stimulation Tests
Lumbar Puncture
Others

Global Multiple Sclerosis Market Size by Route of Administration & CAGR (2026-2033)

Market Overview
Oral
Parenteral
Others

Global Multiple Sclerosis Market Size by Distribution Channel & CAGR (2026-2033)

Market Overview
Hospital Pharmacy
Retail Pharmacy
Online Pharmacy
Others

Global Multiple Sclerosis Market Size by End-Users & CAGR (2026-2033)

Market Overview
Hospitals
Specialty Clinics
Homecare
Others

Global Multiple Sclerosis Market Size & CAGR (2026-2033)

North America (Drug Class, Diagnosis, Route of Administration, Distribution Channel, End-Users)
- US
- Canada
Europe (Drug Class, Diagnosis, Route of Administration, Distribution Channel, End-Users)
- Germany
- Spain
- France
- UK
- Italy
- Rest of Europe
Asia Pacific (Drug Class, Diagnosis, Route of Administration, Distribution Channel, End-Users)
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
Latin America (Drug Class, Diagnosis, Route of Administration, Distribution Channel, End-Users)
- Brazil
- Rest of Latin America
Middle East & Africa (Drug Class, Diagnosis, Route of Administration, Distribution Channel, End-Users)
- GCC Countries
- South Africa
- Rest of Middle East & Africa

Competitive Intelligence

Top 5 Player Comparison
Market Positioning of Key Players, 2025
Strategies Adopted by Key Market Players
Recent Developments in the Market
Company Market Share Analysis, 2025
Company Profiles of All Key Players
- Company Details
- Product Portfolio Analysis
- Company's Segmental Share Analysis
- Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

Biogen Inc. (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Teva Pharmaceutical Industries Ltd. (Israel)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Novartis AG (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Roche Holding AG (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
Key Developments
Merck KGaA (Germany)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Bayer AG (Germany)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Johnson & Johnson (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
AbbVie Inc. (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
TG Therapeutics, Inc. (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Acorda Therapeutics, Inc. (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Alkermes plc (Ireland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
H. Lundbeck A/S (Denmark)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Eli Lilly and Company (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
GlaxoSmithKline plc (United Kingdom)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Pfizer Inc. (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Celgene Corporation (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Mallinckrodt Pharmaceuticals (United Kingdom)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
UCB S.A. (Belgium)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Orion Corporation (Finland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments